RCT-DUPLICATE
RCT-DUPLICATE is a method that uses real-world data, like insurance claims, to mimic randomized clinical trials. It helps see if results from real-world studies match those from traditional trials, especially for evaluating how well medications work in everyday practice.
At a glance
Use when
Evaluating the effectiveness of medical products using real-world data when RCTs are impractical or unethical; supporting regulatory decision-making with external evidence
Avoid when
Highly controlled trial conditions cannot be reasonably approximated with available real-world data; when key confounders are unmeasured or poorly captured in claims
Inputs
Patient-level insurance claims data, RCT protocols, inclusion/exclusion criteria, primary endpoints, comparator definitions, propensity score matching variables
Outputs
Hazard ratios with 95% confidence intervals, regulatory conclusions, concordance assessments between RWE and RCT results
How it works
RCT-DUPLICATE (Randomized, Controlled Trials Duplicated Using Prospective Longitudinal Insurance Claims: Applying Techniques of Epidemiology) is a structured framework for designing nonrandomized real-world evidence (RWE) studies that emulate randomized controlled trials (RCTs). It involves defining study populations, endpoints, and comparators based on existing RCTs, using claims data from US commercial and Medicare payers. Propensity score matching controls for over 120 preexposure confounders. Study protocols and outcome measures are prospectively defined and registered. The method evaluates concordance between RWE-derived hazard ratios and those from original RCTs, assessing whether regulatory conclusions or effect estimates align.
- HTA domains
- Clinical Effectiveness, Costs & Economic Evaluation, Patient and Social Aspects
- Categories
- AppraisalData MappingHeterogeneityRWE
- Assumptions
- Real-world data can approximate RCT conditions when study design emulates trials closely; confounding can be adequately controlled via propensity score matching; study populations derived from claims data are representative enough for valid comparison
- Strengths
- Prospectively defined protocols enhance reproducibility; use of large-scale claims data enables generalizability; rigorous control for confounding via high-dimensional adjustment; direct comparison with RCT benchmarks
- Limitations
- Residual confounding may persist despite matching; differences in population characteristics between RWE and RCTs remain; challenges in accurately emulating trial conditions using observational data; potential bias when using second-generation sulfonylureas as placebo proxies
- Also known as
- RCT DUPLICATE, Randomized Controlled Trials Duplicated Using Prospective Longitudinal Insurance Claims, RCT emulation using claims data
Questions this answers
References & sources
Similar by meaning
Beta record. Generated from the primary source via AI extraction and independent audit, pending final human review.